Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.1799
-0.0227 (-11.20%)
At close: Apr 2, 2026, 4:00 PM EDT
0.1801
+0.0002 (0.11%)
After-hours: Apr 2, 2026, 7:51 PM EDT
Cue Biopharma Employees
Cue Biopharma had 29 employees as of December 31, 2025. The number of employees decreased by 12 or -29.27% compared to the previous year.
Employees
29
Change (1Y)
-12
Growth (1Y)
-29.27%
Revenue / Employee
$947,103
Profits / Employee
-$917,310
Market Cap
17.57M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 29 | -12 | -29.27% | 29 | 0 |
| Dec 31, 2024 | 41 | -12 | -22.64% | 41 | 0 |
| Dec 31, 2023 | 53 | 1 | 1.92% | 53 | 0 |
| Dec 31, 2022 | 52 | -7 | -11.86% | 51 | 1 |
| Dec 31, 2021 | 59 | 7 | 13.46% | 57 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jasper Therapeutics | 27 |
| Lantern Pharma | 24 |
| Citius Pharmaceuticals | 23 |
| SeaStar Medical Holding | 19 |
| Genenta Science | 13 |
| VYNE Therapeutics | 10 |
| Allarity Therapeutics | 7 |
| NanoViricides | 7 |
CUE News
- 8 days ago - Cue Biopharma Announces CEO Transition - GlobeNewsWire
- 9 days ago - Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 - GlobeNewsWire
- 19 days ago - Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 26 days ago - Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - GlobeNewsWire
- 6 weeks ago - Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases - GlobeNewsWire
- 7 weeks ago - Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer - GlobeNewsWire
- 3 months ago - Cue Biopharma Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 3 months ago - Cue Biopharma Announces Proposed Public Offering - GlobeNewsWire